Cover Image

Treatment of systemic mastocytosis with interferon-γ: failure after appearance of anti-IFN-γ antibodies

Abstract. We report a case of a patient with systemic mastocytosis who was treated with interferon-γ. Because of severe diarrhoea, nausea and weight loss due to mast cell infiltration of the gastric mucosa the patient received 150μg d-1 interferon-γ subcutan-eously for 10 months. During therapy, the...

Full description

Saved in:
Bibliographic Details
Main Authors: Fiehn, Christoph (Author) , Prümmer, O. (Author) , Gallati, H. (Author) , Heilig, Bernhard (Author) , Hunstein, Werner (Author)
Format: Article (Journal)
Language:English
Published: August 1995
In: European journal of clinical investigation
Year: 1995, Volume: 25, Issue: 8, Pages: 615-618
ISSN:1365-2362
DOI:10.1111/j.1365-2362.1995.tb01754.x
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1111/j.1365-2362.1995.tb01754.x
Verlag, lizenzpflichtig, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1365-2362.1995.tb01754.x
Get full text
Author Notes:C. Fiehn, O. Prümmer, H. Gallati, B. Heilig, W. Hunstein
Description
Summary:Abstract. We report a case of a patient with systemic mastocytosis who was treated with interferon-γ. Because of severe diarrhoea, nausea and weight loss due to mast cell infiltration of the gastric mucosa the patient received 150μg d-1 interferon-γ subcutan-eously for 10 months. During therapy, the plasma concentrations of IL-3, IL-4 and GM-CSF, which seem to play a role in mast cell growth and differentiation were monitored. The patient had good symptomatic relief and the initially very high eosinophil counts in the pripheral blood showed a partial reduction. However, after 4 months of therapy the patient relapsed. In serum obtained after the relapse, but not in stored serum from the beginning of the therapy, neutralizing antibodies against interferon-γ were found. Therefore an initial response to the therapy and a secondary failure mediated by treatment-induced antibodies against recombinant interferon-γ might be suggested. Interferon-γ may be a well tolerated therapeutic option in systemic mastocytosis. However, treatment-induced neutralizing antibodies against recombinant interferon-γ should be considered if secondary treatment failure occurs.
Item Description:Gesehen am 26.11.2025
Physical Description:Online Resource
ISSN:1365-2362
DOI:10.1111/j.1365-2362.1995.tb01754.x

Similar Items